Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

The Effects of Aplindore on the Treatment of Signs and Symptoms of Parkinson's Disease

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Ligand Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00623324
First received: February 14, 2008
Last updated: September 29, 2011
Last verified: September 2011
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Estimated Study Completion Date: No date given
  Primary Completion Date: July 2008 (Final data collection date for primary outcome measure)